CJC-1295 without DAC + Ipamorelin – Synergistic GH Research Peptide Blend

The CJC-1295 without DAC + Ipamorelin Blend is a dual-peptide research formulation combining a Growth Hormone–Releasing Hormone (GHRH) analogue and a Growth Hormone–Releasing Peptide (GHRP) to create a synergistic model for the study of growth hormone (GH) regulation. This combination enables the investigation of both GHRH receptor–mediated and ghrelin receptor (GHSR)–mediated GH release mechanisms in in-vitro experimental settings.

This reagent is produced under stringent laboratory protocols and tested using High-Performance Liquid Chromatography (HPLC) to confirm a purity of ≥99%. It is supplied as a lyophilized powder for use in controlled in-vitro endocrinological and biochemical research.

Blend Composition

CJC-1295 without DAC – 5 mg: GHRH analogue examined in studies of pulsatile GH release via GHRH receptor activation.
Ipamorelin – 5 mg: GHRP studied for selective activation of ghrelin receptors (GHSR) with minimal observed impact on cortisol and prolactin pathways in in-vitro models.

Key Specifications

Name: CJC-1295 without DAC + Ipamorelin Blend
Total Content: 10 mg (5 mg CJC-1295 without DAC + 5 mg Ipamorelin)
Type: Combination of GHRH and GHRP analogues
Form: Lyophilized Powder
Purity: ≥99% (HPLC tested)
Storage: Store refrigerated, protected from light and moisture
Shelf life: Sealed lyophilizate. Shelf life 24 months from manufacture.

Research Applications

Referenced in research on growth hormone secretion via dual receptor pathways.
Enables investigation of GHRH and GHSR signaling synergy in in-vitro assay models.
Used as a reagent in studies focused on metabolic regulation and GH stimulation protocols.
Supplied in lyophilized form for long-term storage stability and assay reproducibility.

A batch-specific Certificate of Analysis (CoA) is available on request and accompanies every order.

Website Not Available